Protocol Ledger

NCT03573336 · Phase II · TERMINATED

Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis

Interventional Phase II clinical trial protocol NCT03573336 sponsored by Bayer in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-07-04 Enrollment: 8 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03573336
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)8 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03573336
Protocol FieldVerified Registry Value
NCT IdentifierNCT03573336
Consolidated Lead SponsorBayer
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment8 participants (ACTUAL)
Registered Start Date2018-07-04
WhyStopped ClassificationUnspecified

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI